(AP) Swiss pharmaceuticals company Novartis AG said Friday it has produced a first batch of experimental Type A H1N1 Influenza vaccine, a day after the World Health Organization declared the disease a pandemic.

The vaccine hasn't yet been tested and cannot be used in humans yet. It was made in cells, rather than grown in eggs as is usually the case with vaccines, the company said. The vaccine was produced at a Novartis plant in Marburg, Germany.

Vaccines grown in cells currently account for less than 5 percent of the world's vaccine production, and experts say this is unlikely to change soon.

But the news pushed up Novartis shares by 4 percent to 44.82 Swiss francs ($41.56) on the Zurich exchange. The WHO says drugmakers will likely have vaccines against Type A H1N1 Influenza approved and ready for sale after September.

Novartis said more than 30 governments have requested vaccine supplies, including the U.S. Department of Health and Human Service, which placed a $289 million order in May.

For more on the Novartis vaccine

Source: Associated Press